Chattem Unlikely To Buy Bristol Brands Due To Excedrin Aversion
This article was originally published in The Tan Sheet
Executive Summary
Chattem would consider buying one of the smaller brands in Bristol-Myers Squibb's consumer medicines unit, excluding Excedrin, President & COO Alec Taylor reported during a Jan. 20 earnings call